These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27211249)

  • 1. Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option.
    Ramaswamy A; Ostwal V; Pande N; Sahu A; Jandyal S; Ramadwar M; Shetty N; Patkar S; Goel M; Gupta S
    J Gastrointest Cancer; 2016 Sep; 47(3):305-12. PubMed ID: 27211249
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: A large multicenter study by the Association des Gastro-Entérologues Oncologues.
    Brieau B; Dahan L; De Rycke Y; Boussaha T; Vasseur P; Tougeron D; Lecomte T; Coriat R; Bachet JB; Claudez P; Zaanan A; Soibinet P; Desrame J; Thirot-Bidault A; Trouilloud I; Mary F; Marthey L; Taieb J; Cacheux W; Lièvre A
    Cancer; 2015 Sep; 121(18):3290-7. PubMed ID: 26052689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOX-4 as second-line therapy after failure of gemcitabine and platinum combination in advanced gall bladder cancer patients.
    Dodagoudar C; Doval DC; Mahanta A; Goel V; Upadhyay A; Goyal P; Talwar V; Singh S; John MC; Tiwari S; Patnaik N
    Jpn J Clin Oncol; 2016 Jan; 46(1):57-62. PubMed ID: 26603355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of gemcitabine-platinum in Indian patients with advanced gall bladder cancer.
    Sirohi B; Rastogi S; Singh A; Sheth V; Dawood S; Talole S; Ramadwar M; Kulkarni S; Shrikhande SV
    Future Oncol; 2015; 11(8):1191-200. PubMed ID: 25832876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Retroperitoneal Lymphadenopathy (RPLN) on the Outcomes of Locally Advanced Gall Bladder Cancer (GBC) Following Chemotherapy (CT) or Chemotherapy Followed by Consolidation Chemoradiotherapy (CTRT).
    Agrawal S; Naik N; Priyanka P
    J Gastrointest Cancer; 2024 Oct; 56(1):7. PubMed ID: 39425807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.
    Doval DC; Sekhon JS; Gupta SK; Fuloria J; Shukla VK; Gupta S; Awasthy BS
    Br J Cancer; 2004 Apr; 90(8):1516-20. PubMed ID: 15083178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer: A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT).
    Ramaswamy A; Ostwal V; Sharma A; Bhargava P; Srinivas S; Goel M; Patkar S; Mandavkar S; Jadhav P; Parulekar M; Choudhari A; Gupta S
    JAMA Oncol; 2021 Mar; 7(3):436-439. PubMed ID: 33270098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
    Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
    Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
    [No Abstract]   [Full Text] [Related]  

  • 12. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
    Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trial.
    Jang JS; Lim HY; Hwang IG; Song HS; Yoo N; Yoon S; Kim YH; Park E; Byun JH; Lee MA; Oh SJ; Lee KH; Kim BS; Oh SC; Kim SY; Lee SJ
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):641-7. PubMed ID: 19652971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer.
    Hirooka Y; Ishikawa T; Kawashima H; Ohno E; Nonogaki K; Kanamori A; Hirai T; Uchida H; Shirai O; Ishikawa H; Goto H
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):119-125. PubMed ID: 28536803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gemcitabine-cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.
    Ostwal V; Swami R; Patkar S; Majumdar S; Goel M; Mehta S; Engineer R; Mandavkar S; Kumar S; Ramaswamy A
    Med Oncol; 2018 Mar; 35(4):57. PubMed ID: 29564657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infusion chemotherapy with cisplatinum and fluorouracil in the treatment of locally-advanced and metastatic gallbladder cancer.
    Chatni SS; Sainani RS; Mehta SA; Mohandas KM
    J Cancer Res Ther; 2008; 4(4):151-5. PubMed ID: 19052386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best supportive care compared with chemotherapy for unresectable gall bladder cancer: a randomized controlled study.
    Sharma A; Dwary AD; Mohanti BK; Deo SV; Pal S; Sreenivas V; Raina V; Shukla NK; Thulkar S; Garg P; Chaudhary SP
    J Clin Oncol; 2010 Oct; 28(30):4581-6. PubMed ID: 20855823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer.
    Sharma A; Mohanti B; Raina V; Shukla N; Pal S; Dwary A; Deo S; Sahni P; Garg P; Thulkar S; DattaGupta S; Rath G
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):497-502. PubMed ID: 19575200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas.
    Boxberger F; Jüngert B; Brueckl V; Brueckl WM; Hautmann M; Hohenberger W; Hahn EG; Wein A
    Anticancer Drugs; 2003 Jan; 14(1):87-90. PubMed ID: 12544263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.